Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics, metabolomics and single cell proteomics of cells treated with KRASG12D inhibitor MRTX1133

ABSTRACT: The metabolomics data from a multiomics study of the cellular response to a KRASG12D inhibitor, MRTX1133. This repository will accompany the completed bulk pasedDIA analysis of cells treated with inhibitor and approximately 3,000 single cells treated with the same dose and conditions.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Benjamin C Orsburn

PROVIDER: MSV000091110 | MassIVE | Sun Jan 22 05:09:00 GMT 2023

SECONDARY ACCESSION(S): PXD039597

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GNPS - Proteomics, metabolomics and single cell proteomics of cells treated with KRASG12D inhibitor MRTX1133

Project description:The metabolomics data from a multiomics study of the cellular response to a KRASG12D inhibitor, MRTX1133. This repository will accompany the completed bulk pasedDIA analysis of cells treated with inhibitor and approximately 3,000 single cells treated with the same dose and conditions.

2023-01-22 | MSV000091110 | GNPS

MRTX1133 Mechanism of Action Study with Single Cell Proteomics

Project description:Bruker .d files in support of a multiomics analysis of the KRASG12D inhibitor MRTX1133. Files are broken into multiple repositories because uploading 3,000 single cell proteomes plus the bulk proteomics and the metabolomics and the metabolism stuff is really painful. This is the multiplexed (SCOPE2 on a TIMSTOF Flex) .d files for approximately 2,000 single human cells. Metadata will be provided in Orsburn, 2023

2023-01-22 | MSV000091112 | MassIVE

GNPS - MRTX1133 Mechanism of Action Study with Single Cell Proteomics

2023-01-22 | MSV000091112 | GNPS

GNPS - MRTX1133 mechanism of action in KRASG12D mutant cancer cell lines by proteomics and single cell proteomics

Project description:diaPASEF proteomic analysis of KRASG12D mutant cell lines treated with MRTX1133. This dataset is part of a multiomic study featuring the metabolomics and single cell proteomics of 3,000 cells treated with drug. Files are broken into multiple repositories to simplify the deposition and reanalysis of these files.

2023-01-22 | MSV000091111 | GNPS

MRTX1133 mechanism of action in KRASG12D mutant cancer cell lines by proteomics and single cell proteomics

2023-01-22 | MSV000091111 | MassIVE

scRNA-seq data from pancreatic cancer cell lines and tumors treated with MRTX1133 and MRTX849

Project description:Here, we sought to evaluate the impact of KrasG12D and KrasG12C inhibitors on pancreatic cancer cells. A murine pancreatic cancer cell line with KrasG12D mutation was treated with MRTX1133 (KrasG12D inhibitor) and MRTX849 (KrasG12C inhibitor) and scRNA-seq performed to evaluate transcriptional changes. We further evaluated transcriptional changes in cancer cells, as well as in the tumor microenvironment of immunodeficient (NSG) and immunocompetent (C57BL6/J) mice orthotopically implanted with KPC689 cells and spontaneous KPPC tumors in response to MRTX1133 and MRTX849.

2023-06-26 | GSE228502 | GEO

SRT1720 Inhibits the Growth of Bladder Cancer in Organoids and Murine Models through the SIRT1-HIF axis

Project description:Methods: Mouse bladder tumor organoids with Trp53, Pten, Rb1 mutation and Myc, KrasG12D amplification were treated with 10μM SRT1720 and Vehicle for 12 hours respectively. RNA libraries of SRT1720 and vehicle treated mouse bladder organoids were constructed according to standard Illumina protocols, and bulk RNA-seq were performed using Illumina NovaSeq 6000 sequencing platform.

2021-09-01 | GSE155525 | GEO

Comparison of gene expression in cisplatin resistant tumors to chemonaive tumors from a lung cancer mouse model

Project description:Using a mouse model of non-small cell lung cancer driven by activated Kras and loss of p53 (KrasG12D;p53fl/fl), we sought to determine which genes change expression in the bulk tumor after repetitive treatment with cispatin. After tumors were treated multiple times with cisplatin and show no further response, we isolated RNA from tumors treated with cisplatin or a vehicle control (PBS) to determine which genes significantly change in expression in chemoresistant bulk tumors.

2021-11-11 | GSE135720 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of pancreatic tissue transcriptomes from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein

Project description:Purpose: we used next generation sequencing to analyze gene expression profiles of pancreatic tissues from KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein. The goals of this study are to compare the different gene expression profiles of pancreatic tissue between KrasG12D;Pdx1-Cre and miR-301a-/-;KrasG12D;Pdx1-Cre mice treated with caerulein.

2021-06-11 | GSE176571 | GEO

Targeting Senescent Stem-Like Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Project description:Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) is driven by genetic alterations that induce constitutive kinase signaling and is associated with chemoresistance and high relapse risk in children and adults. Preclinical studies in the most common CRLF2-rearranged/JAK pathway-activated Ph-like ALL subtype suggest incomplete oncogene addiction and partial response to tyrosine kinase inhibitor (TKI)-based therapies, highlighting a need to elucidate alternative biologic dependencies and therapeutic vulnerabilities, although the ABL-class Ph-like ALL subtype may be preferentially TKI-sensitive. Using bulk and single-cell multiomics analyses, we profiled residual cells from Ph-like ALL xenograft models treated in vivo with inhibitors to identify mechanisms of potential therapeutic escape. We identified a specific MYC dependency in Ph-like ALL and defined a leukemia cell subpopulation with senescence-associated stem cell-like features regulated by AP-1 transcription factors. This dormant ALL subpopulation could be eradicated by dual pharmacologic inhibition of JAK/STAT and BCL-2, providing mechanistic rationale for alternative therapeutic approaches.

2025-01-28 | PXD053611 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data